GBIO vs. ZNTL, GLSI, FATE, ADCT, OGI, IVA, SLN, IVVD, ACRS, and CDTX
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Zentalis Pharmaceuticals (ZNTL), Greenwich LifeSciences (GLSI), Fate Therapeutics (FATE), ADC Therapeutics (ADCT), Organigram (OGI), Inventiva (IVA), Silence Therapeutics (SLN), Invivyd (IVVD), Aclaris Therapeutics (ACRS), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry.
Generation Bio vs.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.
Zentalis Pharmaceuticals currently has a consensus price target of $8.24, suggesting a potential upside of 340.88%. Generation Bio has a consensus price target of $6.50, suggesting a potential upside of 1,132.23%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Generation Bio is more favorable than Zentalis Pharmaceuticals.
In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Generation Bio. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 3 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.63 beat Zentalis Pharmaceuticals' score of 0.27 indicating that Generation Bio is being referred to more favorably in the news media.
Zentalis Pharmaceuticals received 17 more outperform votes than Generation Bio when rated by MarketBeat users. However, 70.49% of users gave Generation Bio an outperform vote while only 61.86% of users gave Zentalis Pharmaceuticals an outperform vote.
95.2% of Generation Bio shares are held by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 21.1% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Zentalis Pharmaceuticals has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Zentalis Pharmaceuticals' return on equity of -43.91% beat Generation Bio's return on equity.
Generation Bio has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Generation Bio beats Zentalis Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GBIO) was last updated on 3/5/2025 by MarketBeat.com Staff
